BIOVECTRA Launches Specialized Capabilities in mRNA Drug Product Development and Biomanufacturing

BIOVECTRA Launches Specialized Capabilities in mRNA Drug Product Development and Biomanufacturing Today BIOVECTRA celebrates the completion of its $90 million plus biologics expansion at the company’s new state-of-the-art Biomanufacturing Centre with project partners the Government of Canada and Government of…

Read MoreBIOVECTRA Launches Specialized Capabilities in mRNA Drug Product Development and Biomanufacturing

Revolutionizing Healthcare: MedTech StartUps Win $50,000 at ventureLAB’s Third Annual Hard Tech Summit

ventureLAB concluded its 3rd annual HardTech Summit on November 8 & 9 in partnership with York Region, bringing together 800 global leaders, founders, partners, innovators, government officials and regulators both virtually and in person at Toronto Marriott Markham. Canada’s premier technology…

Read MoreRevolutionizing Healthcare: MedTech StartUps Win $50,000 at ventureLAB’s Third Annual Hard Tech Summit
Stevanato

Aya Healthcare Acquires Winnow AI, a Data Science Driven Platform to Recruit Passive Physicians

Aya Healthcare Acquires Winnow AI, a Data Science Driven Platform to Recruit Passive Physicians Aya Healthcare, the largest healthcare talent software and staffing company in the United States, today announced the acquisition of Winnow AI, a data science- driven solution…

Read MoreAya Healthcare Acquires Winnow AI, a Data Science Driven Platform to Recruit Passive Physicians

Phase Genomics Advances Breakthrough Cytogenomics with the Element AVITI System for Acute Myeloid Leukemia

Phase Genomics, Inc., a global innovator for industry-leading genomic solutions, today announced the presentation of new data from the proximity ligation sequencing-based OncoTerra cytogenomics platform on the leading-edge AVITI next-generation sequencing system. The platform offers a revolutionary leap toward rapid…

Read MorePhase Genomics Advances Breakthrough Cytogenomics with the Element AVITI System for Acute Myeloid Leukemia

Paragonix Announces World’s First-In-Human Use of BAROguard™ Donor Lung Preservation System by Leading Academic Medical Center

Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, has successfully completed the world’s first-in-human case utilizing its newest donor lung preservation technology, the BAROguard™ Donor Lung Preservation System, which received FDA 510(k) clearance in August 2023.…

Read MoreParagonix Announces World’s First-In-Human Use of BAROguard™ Donor Lung Preservation System by Leading Academic Medical Center

BioMimetix Presents Data from Phase 2 Study of BMX-001 Demonstrating Increased Survival of 6.6 Months in High Grade Glioma Patients at the 2023 Society for Neuro-Oncology Annual Meeting

BioMimetix JV, LLC, a clinical-stage biotechnology company developing metalloporphyrins, a novel drug class for the treatment of cancer patients, today announced the presentation of encouraging data from its Phase 2 study of lead candidate, BMX-001, for the treatment of high-grade…

Read MoreBioMimetix Presents Data from Phase 2 Study of BMX-001 Demonstrating Increased Survival of 6.6 Months in High Grade Glioma Patients at the 2023 Society for Neuro-Oncology Annual Meeting

Lunovus Enhances Its Eyecare Software and Service Solutions with Acquisition of Diamond Studios

Lunovus Enhances Its Eyecare Software and Service Solutions with Acquisition of Diamond Studios Lunovus LLC, a physician-owned pioneer in the eyecare industry, known for its advanced medical software and eye care supplementation solutions, has officially acquired Diamond Studios, a distinguished…

Read MoreLunovus Enhances Its Eyecare Software and Service Solutions with Acquisition of Diamond Studios

Global Artificial Intelligence in Healthcare Research Report 2023 – ResearchAndMarkets.com

Global Artificial Intelligence in Healthcare Research Report 2023 – ResearchAndMarkets.com The “Global Market for Artificial Intelligence in Healthcare 2023” report has been added to ResearchAndMarkets.com’s offering. As of 2021, the market is estimated to be valued at approximately USD 6.1 billion, with a projected…

Read MoreGlobal Artificial Intelligence in Healthcare Research Report 2023 – ResearchAndMarkets.com

Genome Insight to Unveil Hong Kong Real-World Evidence on Target Enhanced Whole Genome Sequencing at 2023 AACR-KCA Joint Conference

Genome Insight to Unveil Hong Kong Real-World Evidence on Target Enhanced Whole Genome Sequencing at 2023 AACR-KCA Joint Conference Genome Insight, a precision healthcare solutions company advancing whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease,…

Read MoreGenome Insight to Unveil Hong Kong Real-World Evidence on Target Enhanced Whole Genome Sequencing at 2023 AACR-KCA Joint Conference

Avistone Announces the First Approval of Vebreltinib for MET Exon 14 Skipping Non-Small Cell Lung Cancer Opening a New Chapter in MET-targeted Treatment of Lung Cancer

Avistone Announces the First Approval of Vebreltinib for MET Exon 14 Skipping Non-Small Cell Lung Cancer Opening a New Chapter in MET-targeted Treatment of Lung Cancer Avistone Biotechnology Co. Ltd. (“Avistone” or “the Company”), an innovative biotechnology company focused on…

Read MoreAvistone Announces the First Approval of Vebreltinib for MET Exon 14 Skipping Non-Small Cell Lung Cancer Opening a New Chapter in MET-targeted Treatment of Lung Cancer

Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.

Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S. Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in…

Read MoreTeva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.

Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria

Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has raised £4.3M in seed funding to develop…

Read MoreGlox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria